JP2007501621A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007501621A5 JP2007501621A5 JP2006522977A JP2006522977A JP2007501621A5 JP 2007501621 A5 JP2007501621 A5 JP 2007501621A5 JP 2006522977 A JP2006522977 A JP 2006522977A JP 2006522977 A JP2006522977 A JP 2006522977A JP 2007501621 A5 JP2007501621 A5 JP 2007501621A5
- Authority
- JP
- Japan
- Prior art keywords
- antisense oligonucleotide
- pharmaceutical composition
- oligonucleotide
- antisense
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 16
- 239000000074 antisense oligonucleotide Substances 0.000 claims 9
- 238000012230 antisense oligonucleotides Methods 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 claims 5
- 108091027075 5S-rRNA precursor Proteins 0.000 claims 4
- 229910019142 PO4 Inorganic materials 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 235000021317 phosphate Nutrition 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 102100022185 Melanoma-derived growth regulatory protein Human genes 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 125000002091 cationic group Chemical group 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010007710 Cartilage injury Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 claims 1
- 206010023203 Joint destruction Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- STJFYCWYHROASW-UHFFFAOYSA-N O-methyl-glaucamine Natural products CN1CCC2=CC(OC)=C(OC)C=C2C2OC(OC)C3=C4OCOC4=CC=C3C12 STJFYCWYHROASW-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000029033 Spinal Cord disease Diseases 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 230000005714 functional activity Effects 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229940076144 interleukin-10 Drugs 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- PRFXRIUZNKLRHM-UHFFFAOYSA-N l-prostaglandin B2 Natural products CCCCCC(O)C=CC1=C(CC=CCCCC(O)=O)C(=O)CC1 PRFXRIUZNKLRHM-UHFFFAOYSA-N 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims 1
- PRFXRIUZNKLRHM-OSJNIVAESA-N prostaglandin b2 Chemical compound CCCCC[C@H](O)\C=C\C1=C(C\C=C\CCCC(O)=O)C(=O)CC1 PRFXRIUZNKLRHM-OSJNIVAESA-N 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03018285 | 2003-08-12 | ||
| PCT/EP2004/008986 WO2005014812A2 (en) | 2003-08-12 | 2004-08-11 | An antisense oligonucleotide to inhibit melanoma inhibitory activity, mia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007501621A JP2007501621A (ja) | 2007-02-01 |
| JP2007501621A5 true JP2007501621A5 (https=) | 2007-09-27 |
| JP4649408B2 JP4649408B2 (ja) | 2011-03-09 |
Family
ID=34130073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006522977A Expired - Fee Related JP4649408B2 (ja) | 2003-08-12 | 2004-08-11 | 「黒色腫阻害活性（ｍｉａ）」を阻害するアンチセンスオリゴヌクレオチド |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7910563B2 (https=) |
| EP (1) | EP1660656B1 (https=) |
| JP (1) | JP4649408B2 (https=) |
| AT (1) | ATE369422T1 (https=) |
| DE (1) | DE602004008085T2 (https=) |
| ES (1) | ES2289544T3 (https=) |
| WO (1) | WO2005014812A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004008085T2 (de) | 2003-08-12 | 2008-04-24 | Antisense Pharma Gmbh | Antisense-oligonukleotid zur hemmung der melanom-inhibierenden aktivität (mia) |
| CN100562342C (zh) * | 2006-01-17 | 2009-11-25 | 奥林格斯技术有限公司 | 防治流感病毒感染的寡核苷酸药物 |
| EP2580326A1 (en) | 2010-06-11 | 2013-04-17 | Antisense Pharma GmbH | Method for selective oligonucleotide modification |
| ITRM20110134A1 (it) * | 2011-03-22 | 2012-09-23 | Matteo Bordignon | Inibitori di mia (attività inibitoria melanoma) per identificare, prevenire e curare la vitiligine |
| EP3103450A1 (en) * | 2015-06-12 | 2016-12-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | None-hydrophobic compounds for use in treating metastasis and/or cartilage defect |
| CN105250900A (zh) * | 2015-10-21 | 2016-01-20 | 宋军君 | 一种治疗腰椎间盘突出中药 |
| US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
| KR20180103816A (ko) | 2016-02-09 | 2018-09-19 | 오토텔릭 엘엘씨 | 췌장암을 치료하기 위한 조성물과 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0945507A1 (de) * | 1998-03-27 | 1999-09-29 | Boehringer Mannheim Gmbh | Tumorspezifische Expressionskontrollregion und deren Verwendung |
| WO1999065928A2 (en) * | 1998-06-19 | 1999-12-23 | Genzyme Corporation | Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues |
| EP1133994A1 (en) * | 2000-03-11 | 2001-09-19 | Biognostik Gesellschaft für biomolekulare Diagnostik mbH | A method for reversing the immunosuppressive effects of the Melanoma Inhibitory Activity "MIA" |
| AU2001250572A1 (en) * | 2000-04-07 | 2001-10-23 | Epigenomics Ag | Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations |
| DE602004008085T2 (de) | 2003-08-12 | 2008-04-24 | Antisense Pharma Gmbh | Antisense-oligonukleotid zur hemmung der melanom-inhibierenden aktivität (mia) |
-
2004
- 2004-08-11 DE DE602004008085T patent/DE602004008085T2/de not_active Expired - Lifetime
- 2004-08-11 AT AT04763992T patent/ATE369422T1/de active
- 2004-08-11 US US10/567,879 patent/US7910563B2/en not_active Expired - Fee Related
- 2004-08-11 EP EP04763992A patent/EP1660656B1/en not_active Expired - Lifetime
- 2004-08-11 JP JP2006522977A patent/JP4649408B2/ja not_active Expired - Fee Related
- 2004-08-11 WO PCT/EP2004/008986 patent/WO2005014812A2/en not_active Ceased
- 2004-08-11 ES ES04763992T patent/ES2289544T3/es not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7002603B2 (ja) | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド | |
| US20230064031A1 (en) | 4'-phosphate analogs and oligonucleotides comprising the same | |
| JP4443810B2 (ja) | ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ誘導性免疫刺激の調節 | |
| JP7129702B2 (ja) | オーバーハングを有する二本鎖核酸複合体 | |
| JP5650367B2 (ja) | 医薬組成物 | |
| US10322173B2 (en) | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent | |
| US5596091A (en) | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides | |
| JP4118348B2 (ja) | Ｇキャプ安定化したオリゴヌクレオチド | |
| KR101310569B1 (ko) | 안티센스 핵산 | |
| CA2453301A1 (en) | Synthetic double-stranded oligonucleotides for specific inhibition of gene expression | |
| KR20150028352A (ko) | 키랄 핵산 어쥬번트 | |
| JP2012147790A (ja) | エキソンスキッピングを誘発する為の手段及び方法 | |
| JP2017533189A (ja) | ＧａｌＮＡｃホスホラミダイト、その核酸結合体およびそれらの使用 | |
| JP2010528041A5 (https=) | ||
| JP2010503707A (ja) | オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー | |
| RU2020115761A (ru) | МОЛЕКУЛЫ НУКЛЕИНОВЫХ КИСЛОТ ДЛЯ УМЕНЬШЕНИЯ УРОВНЯ мРНК PAPD5 ИЛИ PAPD7 ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННОГО ГЕПАТИТА В | |
| JP2007501621A5 (https=) | ||
| JP4649408B2 (ja) | 「黒色腫阻害活性（ｍｉａ）」を阻害するアンチセンスオリゴヌクレオチド | |
| KR20130068032A (ko) | 안정한 안티센스 올리고뉴클레오티드 접합체 및 그 제조방법 | |
| WO2021157730A1 (ja) | 核酸医薬とその使用 | |
| WO1993015742A1 (en) | Oligonucleotides having zwitterionic moieties | |
| US10731154B2 (en) | Acyl-amino-LNA and/or hydrocarbyl-amino-LNA oligonucleotides | |
| JP6934695B2 (ja) | 核酸医薬とその使用 | |
| JPWO2022250155A5 (https=) | ||
| AU2005218065B2 (en) | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |